CG-806

DRUG2 trials

Sponsors

Aptose Biosciences Inc.

Conditions

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaMyelodysplastic SyndromesNon-Hodgkin's LymphomaSmall Lymphocytic Lymphoma

Phase 1

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

TerminatedNCT03893682

Aptose Biosciences Inc.Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma, Small Lymphocytic Lymphoma

Start: 2019-04-30End: 2024-05-17Updated: 2025-03-07

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

TerminatedNCT04477291

Aptose Biosciences Inc.Acute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2020-10-06End: 2024-04-15Updated: 2025-03-07

Related Papers

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases

Leukemia & lymphoma/Leukemia and lymphoma2024-06-133 citations

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood2023-11-025 citations

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood2022-11-153 citations

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood2022-11-151 citations

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood2021-11-055 citations

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood2021-11-055 citations

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Blood2020-11-048 citations

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Cancer Research2020-08-152 citations

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Cancer Research2020-08-151 citations

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Blood2019-11-133 citations